This is a cell-mediated type of treatment. In the first case (CAR-T cell therapy), the mechanism is implemented as follows: CAR-T cells are extracted from the human body and modified genetically, that is, a so-called chimeric antigen receptor is attached to them, which is responsible for recognizing abnormal elements. Then they are administered back to the patient in the form of a finished drug for subsequent active work on destroying the tumor.
Targeted therapy has similar principles of implementation. But in this case, specialists develop specific antibodies for a specific patient or select drugs that also fulfill their tasks of destroying abnormal cells after entering the human body. These are new types of drugs such as immunostimulants and immunomodulators Keytruda (Pembrolizumab), Nivolumab (Opdivo), Ipilimumab (Yervoy) and some others.
Another amazing property of cell therapy is that monoclonal antibodies can not only be programmed. But also, relatively speaking, “attach” to them special drugs used in radiation or chemotherapy. After entering the human body, these antibodies act as a carrier that delivers the medicine directly to the affected area.